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Background: Burkholderia dolosa can result in chronic airway infection and rapid decline in lung function in patients with cystic ﬁbrosis (CF).
Amiloride has antibacterial properties that may be synergistic with aminoglycosides against other species belonging to the Burkholderia cepacia
complex (Bcc). We attempted to eradicate B. dolosa using a combination of nebulized tobramycin and nebulized amiloride in infected CF patients.
Methods: A 6-month, open-label trial of continuous inhaled amiloride, delivered via nebulization four times daily, and continuous inhaled
tobramycin (TIS or TOBI®) nebulized twice daily, was offered to all CF patients at our institution who are chronically infected with B. dolosa.
Results: Twenty two of 27 patients with B. dolosa were eligible and twelve elected to participate. Eradication of B. dolosa was not noted in any
study subject. While patients tolerated treatment with no adverse effects, there was also no apparent impact on other secondary outcome measures.
Conclusions: Concurrent, continuous inhalation of amiloride and tobramycin for 6 months was not effective for the eradication of chronic B. dolosa
airway infection in CF patients.
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Cystic Fibrosis (CF) is a chronic, progressive, and ultimately
fatal genetic disease [1]. The main physiological defect is related
to abnormalities in ion and water transport across epithelial cells,
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doi:10.1016/j.jcf.2012.06.006clinical manifestations include disruption of mucociliary clear-
ance in the lung resulting in persistent lung infection and
inflammation with progressive lung damage, as well as exocrine
pancreatic insufficiency with consequent malabsorption and poor
weight gain. The prognosis for patients with cystic fibrosis has
gradually improved from a median life expectancy of 5 years of
age in the United States during the 1930's to the 2008 projection
of 37.4 years of age based on Cystic Fibrosis registry data [2], but
lung damage due to chronic airway infection and subsequent
respiratory failure remains the primary cause of death.
Burkholderia cepacia complex (Bcc) bacteria are comprised
of at least 17 species of gram-negative organisms recognized as
important pathogens in the airway of patients with CF.
Chronically infected patients may have an accelerated clinical
decline, and some have experienced “cepacia syndrome,”by Elsevier B.V. All rights reserved.
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pneumonia, and accelerated progression of pulmonary disease
resulting in death within weeks to months [3–7]. Bcc bacteria
are often highly antibiotic resistant, notoriously difficult to treat
and implicated in numerous infectious epidemics within CF
centers. Although initially identified as a single bacterium,
more recent genomic analysis has allowed Burkholderia to be
further speciated [8]. The relative virulence and clinical impact
of these different species remain unclear; however, a recent
report describing the clinical impact of an outbreak of B. dolosa
(genomovar VI) documented a markedly accelerated decline
in lung function as compared to patients colonized with
B. multivorans and patients without Bcc infection [9]. The
clinical impact of this epidemic strain of multiply antibiotic
resistant B. dolosa led us to investigate novel therapies, such as
combined treatment with nebulized amiloride and Tobramycin
solution for inhalation (TIS) or TOBI®.
TOBI, is an established treatment for managing airway
infection in CF [10] Amiloride, however is best known as a
mild, potassium sparing diuretic that inhibits Na+ channel
activity. As a diuretic, it exerts this effect in the distal
convoluted tubule, but it also blocks Na+ channel activity on
the epithelial cell surface. In cystic fibrosis (CF) a defect in Cl−
transport at the apical cell membrane is thought to secondarily
lead to excessive Na+ reabsorption resulting in viscous airway
secretions prone to impaction, airflow obstruction and bacterial
infection. Amiloride has therefore been studied in CF in an
effort to reverse this process by reducing the viscosity and
improving clearance of airway secretions. The effect of
amiloride on the CF airway has been substantiated in vitro in
respiratory epithelial cell culture [11–13] and in vivo [14] by
nasal potential difference measurements across the epithelia of
CF patients, where it corrects the abnormal potential difference.
Nebulized amiloride has also been demonstrated in numerous
trials to have an excellent safety profile [15–19], though studies
of efficacy have rendered mixed results. No statistically
significant effect on various outcomes including FVC, FEV1,
number of hospitalizations, colonization status, and pulmonary
exacerbations was demonstrated in CF patients chronically
colonized with Pseudomonas aeruginosa treated with nebulized
amiloride in combination with standard therapy vs. placebo
(nebulized saline) control [19,20]. However, other trials have
demonstrated improved mucociliary clearance [15,21].
Althoughmore studies exist evaluating the role of amiloride as
a mucolytic in CF, amiloride also has in vitro antimicrobial
properties [22,23] and antimicrobial synergy exists between
amiloride and tobramycin [22–25]. However, the mechanism of
action for the synergy remains speculative. Extracellular sodium
antagonizes tobramycin-related inhibition of Bcc bacteria
proliferation and this effect is reversed by amiloride suggesting
that amiloride may act directly through sodium channels on the
surface of the bacteria [25]. Additionally, several substituted
amine compounds have demonstrated synergy with tobramycin
against Bcc isolates, suggesting the amine group in amiloride
may be an important moiety in the observed synergy [23].
Interestingly, the synergy between amiloride and tobramycin
appears to be more pronounced against Burkholderia cepaciacomplex bacteria than other common CF airway flora such as
P. aeruginosa and Stenotrophomonas maltophilia [24,25] which
may explain mixed results in clinical efficacy in trials involving
patients infected with P. aeruginosa.
A recent case report series provided additional preliminary
support of the synergy seen in vitro. Middleton, Kidd, and
Williams studied the in vivo antimicrobial effect of amiloride
(5 mL of 1 mM solution nebulized 3 times a day) and tobramycin
(80 mg in 2 mL nebulized 3 times a day, immediately following
amiloride inhalation) for up to 6 months in 4 CF patients
colonized with Bcc bacteria (genomovars III, VII, and unknown)
[17]. Eradication of the bacteria from the airways was noted in 3
of the 4 patients studied, and reportedly persisted for at least
2 years. This result is remarkable because it appears to be rare for
Bcc bacteria to be eliminated from the airway in CF once
infection is established. In another study, for example, only 6% of
patients with one respiratory culture positive for B. cenocepacia
had subsequent negative cultures [26]. Middleton's group
defined baseline colonization as more than 3 positive cultures,
thus it might be expected that their rates of spontaneous
resolution would be even lower, making the report of eradication
in 3 out of 4 patients more dramatic. All isolates in the Middleton
study were tobramycin resistant, which lends credence to the in
vitro synergy data noted above.
Given the inherently ill and medically unstable lung disease
in patients chronically infected with B. dolosa, as well as the
established safety profile of nebulized amiloride and nebulized
tobramycin in the CF patient population, we elected to
undertake an open label trial of concurrent administration of
amiloride for inhalation (ASI) and TIS. Our hypothesis was that
the use of these combined therapies could eradicate B. dolosa
infection.
2. Materials and methods
We conducted a 24-week, prospective open label trial of
continuous treatment with ASI and TIS in CF patients infected
with B. dolosa. The trial was approved by Children's Hospital
Boston's (CHB) Internal Review Board Committee on Clinical
Investigation and informed consent was obtained. An indepen-
dent Data and Safety Committee monitored the study.
Eligibility required two B. dolosa respiratory cultures
separated by ≥2 weeks, with the second culture within 30 days
of enrollment. Patients were ineligible if they: had known
sensitivity to amiloride or TIS; used other investigational drugs
within 4 weeks; or had an unstable clinical diagnosis that, in the
Principal Investigator's opinion, compromised patient safety.
The dose of TIS, 300 mg twice daily, is that commonly used
clinically in the United States. The amiloride dose of 4.5 mg in
4.5 mL (3.3 mM solution) via nebulization four times daily
was chosen to provide the maximal dose for which there was
efficacy and stability data. This dose and formulation was
found to meet appearance (no precipitate) and chemical purity/
stability guidelines (b1% w/w of related compound impurities
by HPLC) when stored at room temperature in light-protected
vials for 3 months (reference: Chemistry, Manufacturing, and
Control Section; Serial # 006; August 26, 1991). The dosing
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et al. who administered amiloride (5 mL of a 1 mM solution)
and tobramycin (80 mg) three times daily for 6 months. The
higher doses proposed in this study were thought to potentially
increase the likelihood of efficacy. We also chose a length of
therapy consistent with the greatest prior length of therapy
resulting in eradication. Adherence was monitored by counting
empty amiloride and TIS vials and consistently demonstrated
good compliance. Patients completed study visits on days 7(±1),
28(±3), 84(±7), 168(±7) and 182(±7).
Primary endpoint: eradication of B. dolosa, defined as 3
consecutive negative respiratory cultures. Respiratory cultures
were obtained at each visit and included sputum cultures or
oropharyngeal cultures when sputumwas unavailable. Following
a negative culture, additional cultures were to be obtained after
day 182, no less than 14 days apart, until three negative cultures
or a positive culture was obtained.
Secondary endpoints: study visits included a physical exam,
pulmonary function tests, sputum cultures and additional
laboratory testing. These evaluations were completed at the
screening visit and days 7(±1), 28 (±3) 84(±7), 168 (±7) and
182(±7). Spirometry was performed in compliance with ATS
guidelines on the Morgan Scientific ScreenStar Spriometer using
Knudsen reference values. Blood work included: hematology
(hematocrit, hemoglobin, RBC count, WBC count and differen-
tial, platelets); chemistry (sodium, potassium, chloride, bicarbon-
ate, total bilirubin, alkaline phosphatase, ALT (SGPT), AST
(SGOT), LDH, BUN, creatinine, uric acid, calcium, phosphate,
total protein); serum inflammatory markers (total IgG and
C-reactive protein); tobramycin serum level. Urine was sent for
urinalysis (color, specific gravity, pH, protein, glucose, ketones).
Urine pregnancy test was done at the screening visit for subjects
of childbearing potential. Audiology was performed at baseline
and the end of the study using conventional pure tone audiometry
looking specifically for sensorineural hearing loss. Quality of life
was assessed by age appropriate Cystic Fibrosis Questionnaire-
Revised (CFQ-R) [27] on day 7(±1), 84(±7), and 182(±7).
Amiloride was supplied by Sifavitor (Milan, Italy) and
compounded by the CHB pharmacy to a concentration of 3.3×
10−3 M. 4.5 mL was delivered via Omron MicoAir ultrasonic
nebulizer four times daily; doses were separated by no less than
4 h. This nebulizer was chosen in an effort to reduce the treatmentTable 1
Baseline characteristics. Data are expressed as mean (±SD) or number (%).
Baseline characteristic Amiloride
(N=12)
Age, years 19.1 (±4.9)
Male gender 9 (75%)
Body mass index 20.9 (±2.8)
Pancreatic insufficiency 12 (100%)
FEV1, % predicted
b 67.0 (±15.4)
Months since first positive B. dolosa culture 68.3 (±25.8)
a P-values compare amiloride vs. non-amiloride cohorts.
b FEV1 at the time of screening in study patients and the best FEV1 over the first 3burden because it is portable and nebulized a relatively large
medication volume rapidly. 5 mL of 60 mg/mL TIS solution
(Novartis, USA) was delivered via PARI LC PLUS nebulizer
with DeVilbiss Pulmo-Aide air compressor twice daily. Two
doses of amiloride were administered immediately following
tobramycin.
At trial initiation, our institution followed 27 patients with
B. dolosa; all were offered study participation. 12 patients
enrolled in the trial, 10 of whom completed the study. Two
subjects dropped out due to treatment burden. Three ineligible
patients elected to receive amiloride on a compassionate use
basis outside of the study protocol.
We also reviewed the clinical course of 10 patients infected
with B. dolosa who did not participate in this study. A second
protocol for retrospective analysis of data was approved by our
IRB. 2 non-participants were not included in this review due to
insufficient data. “Baseline” of non-study subjects was assigned
as the date of the highest FEV1 from spirometry performed
during the first three months of study enrollment. For study and
non-study patients we also analyzed all available % predicted
FEV1 results over time from 36 months prior until 18 months
after baseline.
Baseline characteristics of the amiloride and non‐amiloride
cohorts were compared with the t‐test and Fisher's exact test.
Clinical outcomes in study patients were evaluated by subtracting
baseline values and using a paired t‐test on the changes from
baseline. Quantitative culture results were analyzed on a
logarithmic scale. When the quantitative value was reported as
a range (e.g., 107 to 108), we used the midpoint (7.5 logs).
Analysis of percent predicted FEV1 followed methods used in a
previous report on this B. dolosa cohort [9].3. Results
Table 1 shows baseline patient characteristics for enrolled
study patients, non‐study patients who did not receive the study
treatment (“non-amiloride”) and the three patients who received
study treatment through compassionate use protocols. Com-
pared with subjects who did not receive the study treatment, the
study cohort was generally younger and had a longer interval
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Fig. 1. Mean percent predicted FEV1 before and after start of treatment in
patients enrolled in the trial (or corresponding “baseline” date in non-amiloride
cohort). Error bars are ±1 SE. Estimates and SEs are based on a random effects
model [9].
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B. dolosa at baseline, as required for eligibility in the study.
One subject had no repeat culture during the study and a second
subject had only one because he dropped out of the trial. 10 of
12 subjects had ≥3 culture results. All follow‐up cultures were
also positive. Therefore, no patient met the primary endpoint
for eradication of B. dolosa from their airways.
We also analyzed quantitative respiratory cultures of B. dolosa.
To maximize the sample size for this analysis, we used data from
either the Week 24 or Week 26 visits as the “end of treatment”
value, and averaged the two values if both were available
(Table 2). The number of organisms per mL at both baseline and
end of treatment was approximately 7 logs (10,000,000) and there
was no significant change from baseline to end of treatment (n=5
subjects with data at both time points, paired t‐test p= .63). There
was also no trend over time evident when on‐treatment time points
(n=6 at 4 weeks; n=6 at 12 weeks) were considered.
Not including normal flora, bacterial organisms other than
B. dolosa were present in sputum cultures from 3 of 12 (25%)
patients at baseline and the prevalence of other organisms
remained stable at 20–45% throughout the study.
Two inflammatory markers (IgG and C reactive protein),
were analyzed similarly to quantitative cultures. There was no
suggestion of a change from baseline for these outcomes.
Table 2 summarizes the baseline and end of treatment results.
There were no significant differences in quality of life scale
subscale scores between baseline and end of treatment. However,
the treatment burden subscale was marginally significant (p= .07,
Table 2) with a mean decline of 12.5 points on a 0–100 scale. The
change from baseline to 24 weeks was slightly larger (16.7 point
decline, p= .05).
As shown in Fig. 1, the rate of change in percent predicted
FEV1 is similar for study patients and for the non‐amiloride
cohort, with no appreciable change in the rate from before to
after baseline in either cohort. P‐values for comparing rates of
change between cohorts and for changes in rates of decline
from before to after baseline were all N .15. In the study cohort,
the estimated rates of decline are 6.6 and 6.4 percentage points
per year before and after baseline, respectively.
Recognizing that the slopes of the four line segments in Fig. 1
are similar, we fit a simplified model which assumes equal slopes
in order to estimate an overall rate of decline in lung function. TheTable 2
Comparison of baseline with end of treatment in study subjects.
Baseline
N Mean (±SD)
Quantitative B. dolosa culture
(log10 organisms/mL)
7 7.01 (±0.85)
IgG (mg/dL) 12 1511.2 (±431.0)
C-reactive protein (mg/dL) 12 2.01 (±3.92)
Treatment burden d 8 54.2 (±9.3)
a Week 24 or Week 26 (averaged if data available at both time points).
b Number of patients with data at both baseline and end of treatment.
c Paired t‐test.
d Subscale of CFQ-R.estimated rate of decline is 5.1 percentage points per year (95%
CI 3.1 to 7.1). For comparison, our original report documented a
decline of 7.1 points per year (95% CI 4.5 to 9.6) during the
18 months following initial colonization with B. dolosa [9].4. Safety
Nebulized amiloride appeared to be very well tolerated in this
study population. There was a single episode of bronchospasm
which occurred immediately after drug administration and was
thought to be drug related. The patient was treated with a
bronchodilator, had resolution of bronchospasm based on
spirometry, and was observed for 2 h without further symptoms.
Amiloride was subsequently successfully administered following
pretreatment with albuterol and was well tolerated. The patient
completed the study and had no additional complaints or
documented bronchospasm. The most commonly observed AE
overall was fever (14 episodes); however all were thought to be
related to intercurrent illness or infection as opposed to drug
administration. There was no evidence of nephrotoxicity, hepa-
totoxicity or ototoxicity based on monitoring throughout the
study. A mid-study safety evaluation by the Data and Safety
Committee also did not find any adverse impact of therapy.End of treatment a
N Mean (±SD) N b P c
7 6.89 (±0.70) 5 .63
10 1560.8 (±506.7) 10 .99
10 4.43 (±8.85) 10 .46
8 41.7 (±16.5) 8 .07
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In this limited cohort of CF patients we were not able to
demonstrate eradication of B. dolosa from airway cultures
during concurrent therapy with inhaled amiloride and tobra-
mycin. We also did not demonstrate improvement in any other
health outcomes after 24 weeks of treatment.
It is notable that patients who enrolled in this trial were
generally younger as compared to non-participants, and they
tended to have been infected with B. dolosa for a longer period
of time. There was also a trend toward better baseline lung
function in the amiloride group though this did not reach
statistical significance. The decline in FEV1 over time during
the study period was very similar in study participants and
non-participants.
Treatment burden associated with our study was cited as the
reason two of the 12 subjects withdrew. Similarly, the CFQ-R
subscale score associated with treatment burden suggested that
the trial contributed to the treatment burden, though this
measure also did not reach significance.
Our results are in contrast to the previous case report series
from Middleton et al. [17] in which 3 out of 4 patients treated
with nebulized tobramycin and amiloride experienced eradica-
tion of a Burkholderia cepacia complex organism. However, it
is notable that none of the patients in that series was known to
be infected with B. dolosa. B. dolosa appears to be a partic-
ularly drug resistant bacteria among species of Bcc organisms.
The dosage of medications also differed in our trial as
compared to this earlier report. The Middleton study used
tobramycin 80 mg/2 mL TID while we administered TIS
300 mg (60 mg/ml×5 mL) BID. Amiloride in the prior study
was given at a dose of 5 mL of a 1 mM solution TID while we
provided patients with 4.5 mL of a 3.3 mM solution QID. Thus
our total dose of each medication exceeded that administered in
the Middleton report. While these modifications in dosage and
timing seemed reasonable it is possible that we would have had
greater therapeutic efficacy if we had replicated the Middleton
trial more exactly.
In a more recent report of clinical experience with TIS and
amiloride (1.5 mg in 5 mL 0.45% sodium chloride) twice daily
in the treatment of B. cepacia, eradication was achieved in one
of 7 patients [28]. This patient cultured B. cepacia, genomovar
IV for less than two months. The remaining six patients who
did not eradicate B. cepacia were infected for longer periods of
time. It is notable that in Middleton's study the period of
chronic infection prior to the eradication attempt was also
relatively brief while our patients were all infected for years
prior to amiloride/TIS therapy. Thus length of colonization may
be a key factor influencing the prospect of eradication and it may
be reasonable to expect reduced eradication in our population
compared to these reports, independent of Burkholderia geno-
movar status.
Use of inhaled as opposed to systemic antibiotics may also
limit efficacy, since drug may not reach affected areas of lung.
However, orally administered amiloride at clinically acceptable
doses does not result in measurable sputum levels of drug [19],
and evidence suggests that absorption of amiloride from theairway is an active process, with an airway half-life of only
20 min [7]. Thus systemic administration of amiloride is not a
realistic option. And while parenteral administration of tobramy-
cin is common, the toxicity of this associated with long term
administration makes it prohibitive. Of note, the three patients
who received inhaled amiloride outside of the protocol on an
individualized basis were all on intravenous aminoglycosides and
B. dolosa was also not eradicated in these patients.
Our initial report documented a decline in FEV1 of 7.1% per
year following B. dolosa infection as compared to an annual
average FEV1 decline of 2.3% per year prior to infection [9]. In
the current analysis, we estimate a decline of 5.1% per year
after the start of amiloride (or after a similar baseline date for
the non‐study patients), suggesting that patients chronically
infected with B. dolosa continue to suffer rapidly advancing
disease.
Finally, our study was fundamentally limited in several
important ways. First, we have an inherently small patient
population, which limits the power of our results. Additionally
the characteristics of nebulized ASI produced by the nebulizer
were not studied, thus inadequate airway deposition is a potential
explanation for lack of efficacy. Furthermore this study was
designedwithout a control group. The lack of a control group was
an effort to provide a safe and potentially beneficial treatment
option to a group of patients with very few therapeutic choices
who have a high potential for rapid decline in lung function and
death. The cohort of patients who elected not to participate is self‐
selected and any comparison with the study group is subject to
bias.
Future evaluation should include a randomized prospective
trial in patients with less severe lung disease, less well
established airway infection, and other B. cepacia genomovars.
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